CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia

Insulin Resistance Clinical Trial

Official title:

Continuous Glucose Monitoring: An Evaluation of Impact on Improving the Efficiency of Diagnostic Processes and Enhancing Patient Safety in the Management of Reactive and Spontaneous Hypoglycaemia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04452396
• Other study ID #: 265405
• Status: Terminated
• Phase: N/A
• Start date: December 1, 2019
• Est. completion date: January 31, 2023

Study information

• Verified date: December 2023
• Source: Barts & The London NHS Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Use of CGM to determine diagnosis in possible spontaneous or reactive hypoglycaemia. Use of CGM to aid treatment optimisation in spontaneous or reactive hypoglycaemia

Description:

The human body's blood sugar levels are tightly controlled by the hormone insulin, produced by the pancreas. If the pancreas produces too much insulin, then the blood sugar will fall to low levels (hypoglycaemia). Insulin overproduction can happen as a result of the body misreading a change in blood sugar levels after eating (such as after obesity surgery) or through tumours of the pancreas which overproduce insulin (insulinomas). Hypoglycaemia can cause subtle symptoms such as tiredness, poor concentration, or dizziness and if untreated more severe symptoms including fits, coma and death. Low blood sugars can go unnoticed at night and if levels fall frequently, people can lose their ability to notice subtle symptoms. People suspected of having hypoglycaemia require a series of investigations to try and reproduce a low blood sugar under controlled conditions. This often requires an admission to hospital for a few days and multiple finger pricks to test the blood sugar - which patients often find painful. If low blood sugars caused by too much insulin are confirmed then medical treatment is started in the first instance, with surgery possibly following later. The only way to check whether these medications are working is by home fingerprick glucose measurements. If people have low sugars at night or have lost their ability to notice symptoms of low blood sugar, it is very difficult to be sure that the medical treatment is working. The investigators plan to use continuous glucose monitoring probes to measure patient's blood sugar prior to and during admission for formal investigation for hypoglycaemia (alongside conventional fingerprick and blood testing). This might allow us to exclude hypoglycaemia as a cause of their symptoms, avoiding lengthy admissions. The investigators will also use this technology (alongside fingerprick testing) to test how well medical treatment is working in patients with proven hypoglycaemia.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: January 31, 2023
• Est. primary completion date: March 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• phase 1 - under investigation for possible/probable hypoglycaemia
• phase 2 - on medical therapy for established hypoglycaemia
• Must be Able and willing to give informed consent. No vulnerable adults will be included.
• Must be Aged >18 years Can be;
• Any ethnicity
• Any socio economic group
• Either conventional gender, or non-binary.

Exclusion Criteria:

• Must not be unwilling or unable to give consent
• Must not be unable to speak sufficient English to give consent and understand study requirements
• Must not be Aged<18 or >90 years
• Must not be lack capacity to consent
• Must not have an underlying hepatic condition
• Must not have a current excessive alcohol consumption (men regularly consuming >50 units/week, women >35 units/week)
• Must not have Diabetes Mellitus
• Must not be currently using Diabetic medication or insulin
• Must not be currently pregnant
• Must not be on haemo or peritoneal dialysis

Related Conditions & MeSH terms

• Endocrine Gland Neoplasms
• Hypoglycaemia Night
• Hypoglycemia
• Hypoglycemia Non-Diabetic
• Hypoglycemia Unawareness
• Hypoglycemia, Reactive
• Insulin Hypoglycemia
• Insulin Resistance
• Insulinoma
• Insulinoma; Malignant, Pancreas
• Neuro Endocrine Tumours
• Neuroendocrine Tumors
• Spontaneous Hypoglycemia

Intervention

Device:
• use of continuous glucose monitoring
Patients will wear a CGM device whilst undergoing diagnostic testing for reactive/spontaneous hypoglycaemia and then optimisation of anti-hypoglycaemic medication.

Locations

Country	Name	City	State
United Kingdom	St Bartholomew's Hospital, dept of endocrinology	London

Sponsors (1)

Lead Sponsor	Collaborator
Barts & The London NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	study arm 1 - diagnosing hypoglycaemic episodes using Continuous Glucose Monitoring of interstitial fluid as a proxy marker of blood glucose	outpatient - CGM findings reflect patient's fingerprick glucose readings; Episodes of true hypoglycaemia (glucose measurement <4, <3.0, <2.2mmol/L as decided by finger prick glucose testing) are captured by the CGM device	up to 5 days prior to admission for hypoglycaemia investigations
Primary	study arm 1 - diagnosing hypoglycaemic episodes (glucose measurement <4mmol/L) using Continuous Glucose Monitoring of interstitial fluid as a proxy marker of blood glucose	inpatient - CGM findings reflect patient's fingerprick glucose readings; Episodes of true hypoglycaemia (glucose measurement <4, <3.0, <2.2mmol/L, as decided by finger prick glucose testing) are captured by the CGM device Inpatient - 72 hour fast - CGM device calls hypoglycaemia (glucose measurement <4, <3.0, <2.2mmol/L) when fingerprick/lab glucoses also do	up to 5 days in hospital during investigations for hypoglycaemia
Primary	study arm 2 - using Continuous Glucose Monitoring of interstitial fluid as a proxy marker of blood glucose to optimise hypoglycaemia treatment in patients with an established diagnosis of spontaneous or reactive hypoglycaemia	blinded phase - CGM findings reflect patient's fingerprick glucose readings- any episodes of true hypoglycaemia (as decided by fingerprick glucose testing) are captured by CGM device unblinded phase - CGM recordings help with titration of anti hypoglycaemic medications and this reduces overall incidence of hypoglycaemic episodes or duration of time spent in hypoglycaemic range (<4, <3.0, <2.2 mmol/L)	up to 30 days
Secondary	assessing concordance between CGMS and lab/finger prick glucose testing	To determine whether CGM systems accurately record hypoglycaemia and can be used in this context	up to 10 days (study arm 1) or up to 30 days (study arm 2)